Investlytic Investlytic
Log in Free Account
English
🕒 Last update: loading…09/11/2026

Stock Eli Lilly and Company LLY

Eli Lilly and Company — Investlytic score 3/5 on the five criteria.

-
-
60/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 3/5 criteria met. Data as of 03/10/2026.

  • ✅ Price trend passed
  • ✅ Growth passed
  • ❌ Debt failed
  • ❌ P/E failed
  • ✅ Correction passed

Price trend

Overall trend (8 years): the price has been multiplied by at least 1.5.

Price change 2018 → 2019: 13.58%

Price change 2019 → 2020: 28.46%

Price change 2020 → 2021: 63.60%

Price change 2021 → 2022: 32.45%

Price change 2022 → 2023: 59.34%

Price change 2023 → 2024: 32.44%

Price change 2024 → 2025: 39.21%

Price change 2025 → 2026: 6.99%

Price change 2026 (year to date): 6.43%

Financial growth

Revenue CAGR (8 years): 17.17%

Earnings CAGR (8 years): 30.33%

Growth status: positive trend (>1%/yr) in revenue and earnings.

Debt

Debt-to-equity ratio: 1.60

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: 36.29

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 10.19% from the high over 6 months.

Correction between 10.0% and 20.0% (target range).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

Create a free account Log in
02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Eli Lilly and Company45.01.60+7.2 %🔒
AbbVie Inc.28.9–+9.5 %–
AstraZeneca PLC20.20.61+3.9 %–
Amgen Inc.20.86.31+6.1 %–
Pfizer Inc.10.00.78−0.5 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

Create a free account Log in
04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

Create a free account Log in
05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

Create a free account Log in
06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

Create a free account Log in
+

Key reported figures

Revenue, net income and net margin reported by Eli Lilly and Company over the latest fiscal years.

Revenue
65.2 bn USD
fiscal year 2025
Net income
20.6 bn USD
fiscal year 2025
Net margin
31.7 %
fiscal year 2025
Average annual growth
+21.6 %
Revenue growth over 5 years
Average annual growth
+12.6 %
Revenue growth over 10 years
Market cap
1,274 bn USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
202024.5 bn6.2 bn25.2 %n/a
202128.3 bn5.6 bn19.7 %+15.4 %
202228.5 bn6.2 bn21.9 %+0.8 %
202334.1 bn5.2 bn15.4 %+19.6 %
202445.0 bn10.6 bn23.5 %+32.0 %
202565.2 bn20.6 bn31.7 %+44.7 %

Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Eli Lilly and Company over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
solid accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
9.13
safe zone (above 2.99)
Piotroski Score
7 / 9
7 to 9: solid accounts
DCF Value
790.68 USD
DCF below share price · share price 1,368.40 USD, gap -42.2 %
Net Debt / EBITDA
1.00 x
moderate debt
Fiscal year20212022202320242025
Cash and investments3.9 bn2.2 bn2.9 bn3.4 bn7.3 bn
Total Debt16.9 bn16.2 bn25.2 bn33.6 bn42.5 bn
Net Debt13.1 bn14.2 bn22.4 bn30.4 bn35.3 bn
Equity9.0 bn10.6 bn10.8 bn14.2 bn26.5 bn
Total assets48.8 bn49.5 bn64.0 bn78.7 bn112 bn
Operating cash flow7.4 bn7.6 bn4.2 bn8.8 bn16.8 bn
Investments (capex)1.3 bn1.9 bn3.4 bn8.4 bn7.8 bn
Free cash-flow5.4 bn4.6 bn-3.2 bn3.8 bn9.0 bn
Share buybacks1.2 bn1.5 bn750 m2.5 bn4.1 bn
Dividends paid3.1 bn3.5 bn4.1 bn4.7 bn5.4 bn

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)43.83 x
Price / book value29.99 x
Return on Equity (ROE)83.7 %
Return on Invested Capital (ROIC)30.5 %
Net margin31.9 %
Debt / equity1.23 x
Current ratio1.39 x
Interest coverage33.81 x
Free cash-flow yield1.5 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.

+

Valuation and competitors

Eli Lilly and Company compared with its sector on the same exchange and with its main competitors.

Company P/E
43.0
60.7 % above the sector
Sector median P/E
26.8
healthcare, NYSE
Sector over 10 years
22.3
10-year median, range 18.4 to 44.9

Direct competitors

CompanyMarket cap (USD)P/ENet margin
Eli Lilly and Company1,334 bn45.031.7 %
Merck & Co., Inc. MRK369 bn46.628.1 %
Johnson & Johnson JNJ658 bn25.528.5 %
AstraZeneca PLC AZN289 bn20.217.4 %
Pfizer Inc. PFE174 bn10.012.4 %
AbbVie Inc. ABBV521 bn28.96.9 %
Amgen Inc. AMGN252 bn20.821.0 %
Sector median (NYSE)26.8

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on . Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering Eli Lilly and Company publish: ratings, price targets and earnings forecasts.

Majority rating
buy
46 analysts
Average price target
1,433.72 USD
from 940.00 USD to 1,650.00 USD, 63 targets over 12 months
Gap with the share price
+1.1 %
price 1,417.54 USD on 30/10/2026

Breakdown of ratings

strong buy 0buy 34hold 9sell 3strong sell 0

Analysts' average target 1,433.72 USD, DCF value 790.68 USD, share price 1,417.54 USD.

Average target over the last 3 months: 1,432.10 USD (20 targets).

Analyst forecasts

Fiscal yearRevenueNet incomeExpected EPS (range)P/E on this EPSAnalysts
202690.4 bn31.6 bn35.15 (33.40 / 37.79)40.312
2027105 bn44.7 bn49.36 (45.90 / 52.84)28.715
2028118 bn50.8 bn56.62 (47.67 / 73.35)25.09

Amounts in USD, the reporting currency.

Track record against expectations: reported EPS above consensus 11 times over the last 12 releases.

Rating changes (12 months)

DateFirmBeforeAfter
30/10/2026Truist SecuritiesBuyBuy
30/10/2026RBC CapitalOutperformOutperform
30/10/2026Argus ResearchBuyBuy
30/10/2026UBSBuyBuy
30/10/2026JP MorganOverweightOverweight

Source: ratings and forecasts published by analysts, collected on 07/11/2026. An analyst rating or target is not a guarantee.

+

Dividends and earnings

Eli Lilly and Company: dividend history, last distributions, stock splits and earnings releases.

Frequency
quarterly
Last dividend
1.73 USD
ex-dividend on 13/11/2026
Last 12 months
6.69 USD
number of payments: 4
Yield
0.6 %
on the last known price
Years of increases
12
consecutive
Years of payments
54
uninterrupted

● Next ex-dividend date: 13/11/2026, 1.73 USD per share.

01.733.465.196.922007 : 1.70 USD2008 : 1.88 USD20082009 : 1.96 USD2010 : 1.96 USD20102011 : 1.96 USD2012 : 1.96 USD20122013 : 1.96 USD2014 : 1.96 USD20142015 : 2.00 USD2016 : 2.04 USD20162017 : 2.08 USD2018 : 2.25 USD20182019 : 2.58 USD2020 : 2.96 USD20202021 : 3.40 USD2022 : 3.92 USD20222023 : 4.52 USD2024 : 5.20 USD20242025 : 6.00 USD2026 : 6.92 USD2026

Annual dividend per share (USD), adjusted for splits. Light bar: current year, incomplete. Red bar: lower than the previous year.

Latest ex-dividend dates

Ex-dividendAmountPayment
13/11/20261.73 USD10/12/2026
14/08/20261.73 USD10/09/2026
15/05/20261.73 USD10/06/2026
13/02/20261.73 USD10/03/2026
14/11/20251.50 USD10/12/2025
15/08/20251.50 USD10/09/2025
16/05/20251.50 USD10/06/2025
14/02/20251.50 USD10/03/2025

Earnings releases

DatePublished EPSExpected EPSSurprise
29/10/20267.485.71+31.0 %
05/08/20268.386.40+30.9 %
30/04/20268.556.97+22.7 %
04/02/20267.546.91+9.1 %
30/10/20257.025.69+23.4 %
07/08/20256.315.60+12.7 %

Stock splits

DateOperation
16/10/1997split: 2 shares for 1
21/12/1995split: 2 shares for 1
01/05/1989split: 2 shares for 1
30/01/1986split: 2 shares for 1

Factual data: ex-dividend history and earnings calendar, as of 05/11/2026. A past dividend does not guarantee the next one.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Eli Lilly and Company.

Free float
90.1 %
share of freely traded shares
Institutions
88.9 %
4,802 declared holders, 2026Q2
Large funds tracked
38
hold the stock as of 2026Q2
Executives (insiders)
0 / 4
0 purchases, 4 sales in 130 days
US elected officials
26
11 purchases, 15 sales in 12 months

Indices: S&P 500 (since 31/12/1970).

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
Vanguard Group82.0 m88.1 bn1.3 %+1.2 %2025Q4
State Street72.4 m86.9 bn1.3 %+103.4 %2026Q2
BlackRock67.5 m81.0 bn1.2 %+1.7 %2026Q2
Fidelity28.5 m34.1 bn1.5 %+8.1 %2026Q2
Capital Research Global Investors20.9 m25.0 bn3.5 %-15.3 %2026Q2
Geode Capital Management20.3 m24.3 bn1.3 %+0.6 %2026Q2
Morgan Stanley16.2 m19.5 bn1.0 %+5.1 %2026Q2
Capital World Investors15.9 m19.1 bn2.3 %+1.8 %2026Q2

Latest insider transactions

DatePersonSideAmount
02/11/2026Hakim Anatsale7.0 m USD
17/08/2026Jonsson Patriksale7.6 m USD
10/08/2026Zakrowski Donald Asale2.4 m USD
07/08/2026Hakim Anatsale6.0 m USD

Elected officials' disclosures

DateOfficialSideAmount
04/09/2026Ro Khannapurchase$1,001 - $15,000
21/11/2025John Boozmansale$1,001 - $15,000
01/07/2026Michael Rullisale$1,001 - $15,000
02/01/2026Michael Rullipurchase$1,001 - $15,000
02/12/2025Michael Rullisale$1,001 - $15,000

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 08/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
NYSE
IPO: 01/06/1972
ISIN code
US5324571083
Workforce
47,000
full-time employees
Chief executive
David A. Ricks
Next earnings
03/02/2027

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Eli Lilly and Company

What is the Eli Lilly and Company share price?

Latest recorded price: 1,354.00 USD on 06/11/2026, for a market cap of 1,274 bn USD.

What is the revenue of Eli Lilly and Company?

65.2 bn USD for fiscal year 2025, with net income of 20.6 bn USD (net margin 31.7 %).

Does Eli Lilly and Company pay a dividend?

Yes. Latest dividend: 1.73 USD per share, ex-dividend on 13/11/2026. Over 12 months: 6.69 USD. Yield on the latest known price: 0.6 %.

When does Eli Lilly and Company report its next earnings?

The next release is expected on 03/02/2027. EPS expected by analysts: 11.07.

What do analysts say about Eli Lilly and Company?

Out of 46 analysts: 34 buy or strong buy, 9 hold, 3 sell or strong sell. Average price target: 1,433.72 USD, i.e. +1.1 % from the share price.

What is the P/E ratio of Eli Lilly and Company?

Trailing 12-month P/E of 43.0, against 26.8 for the sector median on the same exchange (10-year median: 22.3).

Is Eli Lilly and Company stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US5324571083).

How many employees does Eli Lilly and Company have?

47,000 full-time employees according to the latest published profile.

Who runs Eli Lilly and Company?

David A. Ricks is the company's chief executive.

Which large funds own Eli Lilly and Company?

As of 2026Q2, among the large funds tracked: Vanguard Group, State Street, BlackRock, Fidelity, Capital Research Global Investors.

07

Similar stocks